Search
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approvedPraziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. … Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAmcinonide
go.drugbank.com/drugs/DB00288ApprovedAmcinonide is a corticosteroid.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersLivmoniplimab
go.drugbank.com/drugs/DB18939InvestigationalWith Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. … DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsClove oil
go.drugbank.com/drugs/DB11338ApprovedNutraceuticalThe FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108]. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.
Agkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedThe cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae). … Approximately 99% of all venomous snake bites in the United States are caused by Crotalidae, also known as _pit vipers_.
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigational[A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsCedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells. … Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated
Terfenadine
go.drugbank.com/drugs/DB00342ApprovedWithdrawnIn the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesInternational brands: Terfenadin ALAvalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalAvalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase … [L35160] Late-onset Pompe disease is associated with a range of debilitating physical symptoms, such as progressive muscle weakness, including respiratory muscle weakness, and loss of motor function.